Thursday 22 February 2018
Contact US    |    Archive
PR
5 months ago

Halozyme Licenses New Enhanze Target For $30 Million Upfront Payment, Future Milestones And Royalties

SAN DIEGO, Sept. 14, 2017 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced today

Read on the original site


هذه الصفحة هي مجرد قاریء تلقائي للأخبار باستخدام خدمة الـ RSS و بأن نشر هذه الأخبار هنا لاتعني تأییدها علی الإطلاق.

Moscow vs Red

- espnfc.co

Schooling Congress

- Sputniknews

Shakhtar vs Roma

- espnfc.co
Hashtags:   

Halozyme

 | 

Licenses

 | 

New

 | 

Enhanze

 | 

Target

 | 

For

 | 

Million

 | 

Upfront

 | 

Payment

 | 

Future

 | 
Most Popular (6 hours)

Most Popular (24 hours)

Most Popular (a week)

Categories - Countries
All News
All Countries